South San Francisco, CA-based Oxigene (NASDAQ: [[ticker:OXGN]]), a developer of cancer treatments, named Matthew Loar as its new chief financial officer. Loar was previously CFO of KineMed, a privately held biotech in Emeryville, CA.
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
View all posts by Alex Lash
